Understanding and overcoming innate and acquired MAPK-inhibition resistance in anaplastic thyroid cancer

Abstract excerpt

Anaplastic thyroid cancer (ATC) is one of the most lethal human cancers, with some patients succumbing to the disease within weeks of diagnosis. Although a subset of patients with ATC with BRAF V600E mutation respond to the monomeric type I RAF inhibitor (RAFi) dabrafenib in combination with MEK inhibitor (MEKi) trametinib, most rapidly develop adaptive or acquired resistance. These patients, along with those who...

Topics

Open a Topic to create a Post that cites this publication.

• Biomarkers, Tumor
• Disease Management
• MAP Kinase Signaling System
• Molecular Targeted Therapy
• Mutation
• Protein Kinase Inhibitors
• Thyroid Carcinoma, Anaplastic
• Thyroid Neoplasms

Identifiers and source

Literature Corpus work

b1bf7210-9929-590d-be21-c283fdfff942

DOI

10.1101/2024.12.04.24318267